Videos

Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, Dr. Angela Fleishman and Kapila Viges answer questions about clinical trials during the CURE Educated Patient MPN Summit.

A shared discussion on the importance of enrolling in clinical trials for EGFR exon 20–positive NSCLC and improving access to novel therapy for patients.

Watch Kapila Viges, from the MPN Research Foundation, discuss clinical trials, during the CURE Educated Patient MPN Summit.

A focused conversation on how a patient can maintain and improve quality of life while receiving therapy for non–small cell lung cancer.

Watch Dr. Angela Fleishman, from the University of California Irvine, discuss novel agents and clinical trials in polycythemia vera, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, Dr. Aaron Gerds and Dr. Bart Scott, answer questions during the diagnoses and treatment panel during the CURE Educated Patient MPN Summit.

Actor and cancer advocate Patrick Dempsey explains that when a loved one is diagnosed with cancer, it is important that family members make the moments they share together count.

Watch Dr. Bart Scott, from Fred Hutchinson Cancer Center, discuss current treatment options, during the CURE Educated Patient MPN Summit.

A nurse navigator explains how people in their profession create bonds with their patients and guide them through the cancer experience.

Watch Dr. Aaron Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss approaches to diagnosing and assessing symptoms, during the CURE Educated Patient MPN Summit.

Comprehensive discussion on support for patients receiving therapy for NSCLC, ranging from care team members to education materials to support groups.

Looking at available novel therapy for EGFR exon 20 insertion–positive NSCLC, experts consider how patients can play a part in identifying their best treatment option.

Before closing out their discussion on differentiated thyroid cancer, patients and health care professionals alike consider unmet needs in this space.

When it comes to learning about their disease, patients with cancer can have different preferences, from wanting to discuss treatments with their providers or read handouts, while others may not want to know much at all.

An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.

A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.

Mental wellbeing is more of a focus than ever before in cancer care, and while treatments continue to get better, there is still a long road ahead, according to Patrick Dempsey.

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC.

Shared practical advice for patients who may be undergoing treatment for iodine-refractory differentiated thyroid cancer.

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.